www.idosr.org
Serunjogi, 2025
©IDOSR PUBLICATIONS
ISSN: 2579-0781

International Digital Organization for Scientific Research
IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 31-38, 2025.
https://doi.org/10.59298/IDOSR/JES/112.3138
IDOSRJES11200000

Nanovaccines and Immunomodulatory Nanoparticles for Preventing Obesity-Induced Diabetes

Serunjogi Ruth

Department of Clinical Pharmacy Kampala International University Uganda
Email: ruth.serunjogi@studwc.kiu.ac.ug

ABSTRACT

Obesity-induced type 2 diabetes mellitus (T2DM) is a growing global health concern driven by chronic low-grade inflammation, insulin resistance, and impaired metabolic homeostasis. Conventional therapies such as lifestyle interventions, antidiabetic drugs, and bariatric surgery offer only partial benefits and are limited by poor long-term compliance, side effects, and relapse of metabolic dysfunction. In recent years, nanotechnology-based immunotherapeutics particularly nanovaccines and immunomodulatory nanoparticles have emerged as promising strategies for tackling the underlying immunometabolic derangements that link obesity to T2DM. Nanovaccines are designed to induce protective immune responses against obesity-associated inflammatory mediators or to enhance tolerance to metabolic antigens, thereby restoring immune balance. Immunomodulatory nanoparticles, on the other hand, can reprogram immune cells such as macrophages, dendritic cells, and T lymphocytes to reduce systemic inflammation and improve insulin sensitivity. These nanoplatforms can be engineered for targeted delivery, controlled release, and co-delivery of antigens with adjuvants, enabling precise modulation of the immune system. Preclinical studies have demonstrated that such nanomedicines attenuate adipose tissue inflammation, preserve pancreatic β-cell function, and improve glucose homeostasis. However, challenges such as biosafety, large-scale production, regulatory approval, and long-term immunological consequences remain to be addressed before clinical translation. This review provides a comprehensive overview of the mechanisms, design principles, recent advances, and future directions of nanovaccines and immunomodulatory nanoparticles in preventing obesity-induced diabetes.

Keywords: nanovaccines, immunomodulatory nanoparticles, obesity-induced diabetes, metabolic inflammation, immunotherapy

INTRODUCTION

The rising prevalence of obesity and type 2 diabetes mellitus (T2DM) has become one of the greatest public health challenges of the 21st century[1–4]. According to recent epidemiological estimates, over 650 million adults worldwide are obese, and more than 500 million live with diabetes, with T2DM accounting for more than 90% of cases. The intersection of these two conditions has created a dual epidemic, often referred to as "diabesity," which contributes significantly to global morbidity, mortality, and healthcare expenditures[5–7]. Unlike the historical perspective that framed obesity as a mere outcome of caloric imbalance, current scientific understanding highlights it as a complex metabolic and immunological disease. This shift in paradigm is largely attributed to the discovery that adipose tissue is not just an inert storage depot for fat but a highly dynamic endocrine and immune organ[8].

In obesity, adipose tissue undergoes pathological remodeling, marked by adipocyte hypertrophy, hypoxia, and fibrosis[9–11]. These changes trigger infiltration of immune cells, including macrophages, neutrophils, and T lymphocytes, which establish a chronic state of low-grade inflammation. This adipose tissue inflammation is not confined locally but spills over systemically, releasing pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and resistin.[12] These inflammatory mediators interfere with insulin receptor signaling in peripheral tissues, ultimately reducing glucose uptake, impairing glycogen synthesis, and contributing to insulin resistance. Over time, this chronic inflammatory stress also damages pancreatic β-cells, leading to impaired insulin secretion and the clinical manifestation of T2DM.

Traditional approaches to managing T2DM such as lifestyle modifications, oral hypoglycemic drugs, and insulin therapy are primarily palliative. They address hyperglycemia and related symptoms but fail to directly reverse or prevent the immunometabolic dysfunction underlying the disease[13–15]. Moreover, these treatments are not without limitations: patients frequently experience poor adherence due to side effects like weight gain, hypoglycemia, or gastrointestinal discomfort. Furthermore, while drugs such as metformin or sulfonylureas can delay progression, they do not halt the trajectory toward diabetic complications such as cardiovascular disease, neuropathy, nephropathy, and retinopathy[16].

The emerging field of immunometabolism offers a novel way forward by focusing on the interplay between metabolic pathways and immune responses. This interdisciplinary approach views obesity-induced diabetes not simply as an endocrine or metabolic disorder but as a chronic inflammatory disease with immunological roots[17]. Consequently, therapies that can recalibrate the immune system and attenuate chronic inflammation hold the promise of addressing the root cause rather than just the symptoms of T2DM. Nanotechnology has emerged as a particularly promising tool in this regard. Nanovaccines and immunomodulatory nanoparticles offer unique advantages by combining precision targeting with immune-modifying capabilities[18]. Nanovaccines are engineered to mimic pathogenic structures or antigens, thereby training the immune system to mount a controlled response against obesity-associated inflammatory triggers[19–21]. Immunomodulatory nanoparticles, on the other hand, can deliver anti-inflammatory molecules, nucleic acids, or biologics directly to inflamed adipose tissue or immune cells, enhancing therapeutic efficacy while minimizing systemic side effects[22–24]. By intervening at the level of immune dysfunction, these nanoscale platforms offer the potential to restore metabolic homeostasis, preserve β-cell function, and prevent progression to overt diabetes. This review article explores the promise of nanovaccines and immunomodulatory nanoparticles in preventing obesity-induced diabetes. First, we discuss the immunopathological mechanisms linking obesity and T2DM, with particular attention to adipose tissue inflammation, immune cell dysregulation, and systemic metabolic consequences. We then examine how nanomedicine-based immunotherapies exploit these mechanisms, highlighting recent preclinical studies that demonstrate efficacy in restoring insulin sensitivity and glucose homeostasis. Finally, we outline translational challenges—including safety, regulatory considerations, and scalability—that must be addressed to move these innovative therapies from bench to bedside. In doing so, we hope to underscore the transformative potential of nanotechnology at the crossroads of immunology and metabolism.

2. Immunopathology of Obesity-Induced Diabetes (Expanded to ~600 words)

The pathophysiology of obesity-induced diabetes is rooted in a complex interplay between immune dysregulation and metabolic dysfunction. At the center of this interaction is adipose tissue, which undergoes dramatic changes as obesity progresses[25]. Under healthy conditions, adipose tissue functions as a metabolic buffer, storing excess energy in the form of triglycerides and releasing adipokines that regulate appetite, insulin sensitivity, and lipid metabolism. However, in obesity, adipocytes expand beyond their physiological capacity, leading to cellular stress, hypoxia, and even necrosis.[25] These stressed adipocytes release chemokines such as monocyte chemoattractant protein-1 (MCP-1), which recruit circulating monocytes and other immune cells into adipose depots.

Once inside adipose tissue, monocytes differentiate into macrophages, predominantly adopting the pro-inflammatory M1 phenotype. These macrophages, along with infiltrating neutrophils, natural killer cells, and T lymphocytes, form a pro-inflammatory microenvironment. The result is a significant increase in the secretion of cytokines such as TNF-α, IL-6, and interleukin-1β (IL-1β). These cytokines impair insulin receptor substrate (IRS) signaling by activating serine kinases that phosphorylate IRS proteins at inhibitory sites, thereby blocking insulin's ability to stimulate glucose uptake in skeletal muscle and adipose tissue[26]. This defect in insulin signaling is one of the earliest hallmarks of systemic insulin resistance.

In addition to macrophage-driven inflammation, obesity alters adaptive immune responses. CD4+ T helper cells skew toward the Th1 phenotype, producing interferon-gamma (IFN-γ), which further activates macrophages and amplifies inflammation. CD8+ cytotoxic T cells infiltrate adipose tissue, releasing perforin and granzymes that cause adipocyte damage and exacerbate immune activation[26–29]. Meanwhile, regulatory T cells (Tregs), which normally suppress immune responses and maintain tolerance, are significantly reduced in obese adipose tissue. This imbalance between pro-inflammatory and regulatory immune cells perpetuates a vicious cycle of chronic inflammation.

The consequences of this immune activation extend beyond adipose tissue. In the liver, excess free fatty acids and cytokines contribute to hepatic steatosis and insulin resistance, impairing the liver's ability to regulate glucose production[30]. Kupffer cells (resident hepatic macrophages) and infiltrating monocyte-derived macrophages secrete inflammatory mediators that promote progression to non-alcoholic fatty liver disease (NAFLD) and exacerbate systemic insulin resistance. Similarly, in skeletal muscle—the primary site of glucose disposal—lipid accumulation activates toll-like receptors (TLRs) and pro-inflammatory signaling cascades, reducing glucose uptake and glycogen synthesis[31].

Perhaps most critically, the pancreas itself is not spared from immune-mediated damage. Chronic systemic inflammation places sustained stress on pancreatic β-cells, which are already highly sensitive to metabolic insults. Cytokines such as IL-1β and TNF-α directly impair β-cell function by inducing oxidative stress, endoplasmic reticulum stress, and apoptosis. Over time, this results in reduced insulin secretion, compounding the effects of peripheral insulin resistance and leading to persistent hyperglycemia[32].

The immune system's contribution to T2DM is further evidenced by genetic and experimental studies. For instance, mice lacking MCP-1 or its receptor CCR2 show reduced macrophage infiltration and improved insulin sensitivity, underscoring the causal role of chemokine-driven immune activation. Likewise, interventions that expand Tregs or suppress pro-inflammatory cytokines improve glucose tolerance and delay diabetes onset in preclinical models[33].

Taken together, these findings highlight the central role of immunopathology in obesity-induced diabetes. It is not simply the accumulation of excess adipose tissue but the maladaptive immune response to adipose expansion that drives systemic metabolic dysfunction. By sustaining a chronic state of low-grade inflammation, the immune system transforms obesity from a benign energy-storage condition into a fertile ground for T2DM development. This understanding provides a compelling rationale for targeting immune pathways—whether through biologics, small molecules, or nanotechnology-based immunotherapies—as a strategy to prevent or delay the progression of diabetes in obese individuals.

3. Nanovaccines in Preventing Obesity-Induced Diabetes

3.1 Concept and Mechanism

Nanovaccines represent a cutting-edge approach in immunotherapy, employing nanoscale carriers to deliver specific antigens and immune adjuvants with precision and efficiency. These formulations exploit the unique properties of nanoparticles including high surface area-to-volume ratios, tunable surface chemistry, and controlled release kinetics to enhance the delivery and presentation of antigens to immune cells[19, 34]. Unlike conventional vaccines, which predominantly target infectious pathogens, nanovaccines in the context of obesity-induced diabetes focus on modulating immune responses against metabolic antigens or inflammatory mediators that drive chronic low-grade inflammation, a hallmark of obesity and insulin resistance.

Mechanistically, nanovaccines achieve enhanced immunogenicity through multiple pathways. First, their nanoscale size facilitates efficient uptake by antigen-presenting cells (APCs), particularly dendritic cells (DCs), which are critical for initiating immune responses[35]. Upon internalization, nanoparticles undergo endosomal processing, allowing antigens to be cross-presented on major histocompatibility complex (MHC) molecules to T cells. This process can be tailored to induce either immune tolerance attenuating autoimmune-like responses against metabolic tissues or protective immunity that neutralizes specific pro-inflammatory mediators. The incorporation of immune adjuvants further amplifies the desired response by stimulating pattern recognition receptors, such as toll-like receptors (TLRs), enhancing cytokine production, and promoting the differentiation of T cell subsets critical for metabolic homeostasis[36].

Additionally, nanovaccines can be engineered to respond to specific physiological cues, such as pH or enzymatic activity in inflamed adipose tissue, ensuring spatiotemporal control over antigen release. By fine-tuning the size, composition, and surface properties of nanoparticles, researchers can dictate their biodistribution, cellular uptake, and immunological outcome[37]. This precision enables the design of personalized nanovaccine strategies for patients with obesity-induced metabolic disorders, potentially correcting immune dysfunction at an early stage before irreversible tissue damage occurs. Overall, nanovaccines offer a versatile platform for targeted immune modulation, bridging the fields of nanotechnology, immunology, and metabolic disease therapeutics.

3.2 Preclinical Applications

Preclinical studies have provided compelling evidence for the potential of nanovaccines in managing obesity-induced diabetes through immunomodulation. One of the key therapeutic targets is the chronic inflammation observed in adipose tissue, which contributes directly to insulin resistance[38]. In animal models, nanovaccine formulations encapsulating pro-inflammatory cytokines such as TNF-α, interleukin-6 (IL-6), or IL-1β have successfully induced neutralizing antibodies, attenuating local and systemic inflammation. For instance, biodegradable polymer-based nanoparticles delivering peptide antigens against TNF-α have been shown to reduce macrophage infiltration into adipose tissue, lower circulating inflammatory markers, and improve glucose tolerance in obese mice[39].

Beyond cytokine-targeted strategies, emerging approaches leverage the gut–metabolic axis. Obesity is often associated with dysbiosis, resulting in increased gut-derived endotoxins such as lipopolysaccharides (LPS), which trigger systemic inflammation. Preclinical nanovaccine studies have demonstrated that targeting microbial antigens or LPS-derived molecules can prevent inflammatory signaling cascades, improving insulin sensitivity and metabolic homeostasis[40].

Another avenue involves tolerogenic nanovaccines that aim to recalibrate immune responses rather than elicit strong inflammatory reactions. These vaccines can induce regulatory T cells (Tregs) and anti-inflammatory cytokines, promoting immune tolerance toward metabolic tissues such as pancreatic islets and adipose tissue.

Studies using murine models of diet-induced obesity show that such nanovaccines can preserve pancreatic β-cell function, reduce hyperglycemia, and prevent progression toward overt type 2 diabetes[41].
Collectively, preclinical data suggest that nanovaccines offer a multifaceted approach: they can reduce pro-inflammatory signaling, modulate immune cell profiles, and improve insulin sensitivity. Importantly, these studies establish proof-of-concept for the translation of nanovaccine platforms into clinical interventions for metabolic disorders, highlighting their potential as both preventive and therapeutic strategies in obesity-induced diabetes.

3.3 Advantages

Nanovaccines offer several distinct advantages over conventional immunotherapies and systemic treatments for obesity-related metabolic disorders. First, their ability to achieve controlled and sustained release of antigens and adjuvants enhances efficacy while reducing the frequency of administration[42]. This kinetic control minimizes fluctuations in immune activation, which is particularly important in chronic conditions like obesity-induced diabetes, where persistent inflammation must be managed carefully to prevent tissue damage[42].
Second, nanovaccines provide targeted delivery to specific tissues or immune cells. By modifying the nanoparticle surface with ligands or antibodies, formulations can preferentially bind dendritic cells, macrophages, or inflamed adipose tissue, ensuring that immune modulation occurs precisely where it is needed[43]. This site-specific targeting reduces systemic exposure and the risk of off-target immune activation, which is a common limitation of conventional immunotherapies. Another advantage lies in the multiplexing capability of nanovaccines. Multiple antigens and adjuvants can be co-encapsulated within a single nanoparticle, enabling simultaneous modulation of several immune pathways. For obesity-induced diabetes, this allows concurrent targeting of pro-inflammatory cytokines, metabolic antigens, and immune checkpoints, maximizing therapeutic benefit[44].
The physicochemical properties of nanoparticles also enhance cellular uptake and stability. Their small size facilitates endocytosis by immune cells, and surface modifications—such as PEGylation or ligand attachment improve circulation time, biodistribution, and antigen presentation efficiency. Additionally, nanoparticles are often biodegradable and biocompatible, reducing long-term toxicity[45].
Finally, nanovaccines can be tailored for personalized medicine. By incorporating patient-specific metabolic antigens or immune profiles, these vaccines could offer individualized interventions that address the heterogeneity in obesity-associated diabetes[46]. Taken together, these advantages make nanovaccines a versatile and promising strategy for safe, effective, and precise immune modulation in metabolic disorders.

4.1 Mechanism of Action

Immunomodulatory nanoparticles are engineered to directly influence immune cell behavior, particularly in the context of obesity-induced chronic inflammation. Obesity creates an inflammatory milieu in adipose tissue, characterized by excessive infiltration of macrophages and dysregulated cytokine signaling, which contributes to insulin resistance and metabolic dysfunction[47]. Immunomodulatory nanoparticles counteract these effects by delivering bioactive molecules such as small-molecule anti-inflammatory drugs, nucleic acids (siRNA, miRNA), or immunoregulatory proteins directly to immune cells[47].
Mechanistically, these nanoparticles can reprogram macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, restoring tissue homeostasis. They also target dendritic cells, reducing antigen presentation of pro-inflammatory signals, or enhance regulatory T cell (Treg) activity, promoting immune tolerance[48]. Nucleic acid-loaded nanoparticles can silence key pro-inflammatory pathways; for example, siRNA targeting TNF-α or NF-κB effectively reduces transcription of inflammatory mediators. This precision allows modulation of specific immune pathways without broadly suppressing the immune system, which is a major limitation of conventional immunosuppressants. In addition to cellular reprogramming, immunomodulatory nanoparticles benefit from improved pharmacokinetics. Their nanoscale size ensures efficient tissue penetration and cellular uptake, while surface modifications allow selective targeting to inflamed adipose tissue or lymphoid organs. Controlled release mechanisms further maintain therapeutic concentrations over extended periods, reducing dosing frequency.[48] Collectively, these properties enable nanoparticles to recalibrate immune responses, attenuate chronic inflammation, and improve insulin sensitivity in obesity-associated metabolic disorders.

4.2 Examples and Advances

Recent advances in immunomodulatory nanoparticle research highlight their potential in treating obesity-related inflammation and metabolic dysfunction. Several studies have explored the use of nanoparticles loaded with anti-inflammatory phytochemicals such as curcumin and resveratrol, which accumulate in adipose tissue and suppress pro-inflammatory cytokine production. Synthetic drugs, including dexamethasone-loaded nanoparticles, have also been shown to reduce local inflammation while minimizing systemic side effects[49].
Moreover, nanoparticles delivering nucleic acids have demonstrated remarkable precision in immune modulation. siRNA nanoparticles targeting TNF-α, NF-κB, or other inflammatory pathways significantly reduce systemic and adipose tissue inflammation in animal models of diet-induced obesity. Likewise, miRNA

mimics delivered via nanoparticles can enhance Treg differentiation and activity, further contributing to the restoration of immune balance[50].

Beyond preclinical applications, researchers are developing multifunctional nanoparticles capable of both therapeutic delivery and diagnostic imaging (theranostics), allowing real-time monitoring of immune responses and inflammation resolution. Such innovations could guide personalized interventions for obesity-induced metabolic disorders.

4.3 Advantages Over Conventional Therapy

Immunomodulatory nanoparticles present multiple advantages over traditional systemic therapies. Their ability to deliver drugs or nucleic acids directly to specific immune cells or inflamed tissues reduces off-target effects and systemic toxicity. Controlled release and prolonged action minimize frequent dosing, enhancing patient compliance[51]. Nanoscale size improves cellular uptake and biodistribution, while surface engineering allows tissue-specific targeting. Unlike conventional immunosuppressants, which broadly inhibit immune function, nanoparticles can selectively modulate pro-inflammatory pathways, restoring immune homeostasis without compromising host defense[52]. Overall, these properties position immunomodulatory nanoparticles as a precise, safe, and efficient alternative to conventional therapies in managing obesity-related inflammation and metabolic dysfunction.

5. Challenges and Future Directions

Despite significant progress, the clinical application of nanovaccines and immunomodulatory nanoparticles faces several challenges. First, ensuring the long-term safety of these nanomaterials is essential, as prolonged immune modulation could result in unintended immunosuppression or autoimmunity. Second, large-scale production of reproducible nanomedicines remains a technical hurdle. Regulatory pathways for nanovaccines targeting metabolic diseases are still underdeveloped compared to infectious disease vaccines. Moreover, the variability in obesity and diabetes pathophysiology across individuals suggests that personalized nanomedicine approaches may be required.

Future directions include the development of biodegradable and biocompatible nanomaterials, combination therapies that integrate lifestyle interventions with nanomedicine, and advanced delivery systems capable of sensing metabolic cues for responsive drug release. Clinical trials will be crucial to translate promising preclinical findings into real-world applications.

CONCLUSION

Nanovaccines and immunomodulatory nanoparticles represent a paradigm shift in preventing obesity-induced diabetes by targeting the immunological roots of metabolic dysfunction. By restoring immune balance, reducing chronic inflammation, and preserving insulin sensitivity, these nanosystems hold great promise as next-generation therapeutics. Continued innovation in design, safety evaluation, and regulatory frameworks will be critical to unlocking their full potential in combating the global diabetes epidemic.

REFERENCES

1. Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Di Maio, G., Monda, M., La Marra, M.: Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare. 13, 1437 (2025). https://doi.org/10.3390/healthcare13121437
2. Baliou, S., Apetroaei, M.-M., Hatzidaki, E., Kuzmin, S.V., Tzatzarakis, M.N., Arsene, A.L., Tsatsakis, A., Ioannou, P.: The Interplay Between Obesity and Type 2 Diabetes: Common Pathophysiological Mechanisms Contributing to Telomere Shortening. Life. 15, 873 (2025). https://doi.org/10.3390/life15060873
3. Chandrasekaran, P., Weiskirchen, R.: The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. Int J Mol Sci. 25, 1882 (2024). https://doi.org/10.3390/ijms25031882
4. Fu, L., Baranova, A., Cao, H., Zhang, F.: Gut microbiome links obesity to type 2 diabetes: insights from Mendelian randomization. BMC Microbiology. 25, 253 (2025). https://doi.org/10.1186/s12866-025-03968-8
5. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J Cell Mol Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
6. Alum, E.U., Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obesity Medicine. 56, 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
7. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. Journal of Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z

8. Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C.G., Jiang, T.: Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 13, 2403–2424 (2023). https://doi.org/10.1016/j.apsb.2023.01.012
9. Andrade, S., Morais, T., Sandovici, I., Seabra, A.L., Constância, M., Monteiro, M.P.: Adipose Tissue Epigenetic Profile in Obesity-Related Dysglycemia - A Systematic Review. Front Endocrinol (Lausanne). 12, 681649 (2021). https://doi.org/10.3389/fendo.2021.681649
10. Auger, C., Kajimura, S.: Adipose Tissue Remodeling in Pathophysiology. Annu. Rev. Pathol. Mech. Dis. 18, 71–93 (2023). https://doi.org/10.1146/annurev-pathol-042220-023633
11. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481
12. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
13. Gong, D., Lei, J., He, X., Hao, J., Zhang, F., Huang, X., Gu, W., Yang, X., Yu, J.: Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue. Lipids in Health and Disease. 23, 322 (2024). https://doi.org/10.1186/s12944-024-02300-z
14. Gonzalez-Franquesa, A., Gama-Perez, P., Kulis, M., Szczepanowska, K., Dahdah, N., Moreno-Gomez, S., Latorre-Pellicer, A., Fernández-Ruiz, R., Aguilar-Mogas, A., Hoffman, A., Monelli, E., Samino, S., Miró-Blanch, J., Oemer, G., Duran, X., Sanchez-Rebordelo, E., Schneeberger, M., Obach, M., Montane, J., Castellano, G., Chapaprieta, V., Sun, W., Navarro, L., Prieto, I., Castaño, C., Novials, A., Gomis, R., Monsalve, M., Claret, M., Graupera, M., Soria, G., Wolfrum, C., Vendrell, J., Fernández-Veledo, S., Enríquez, J.A., Carracedo, A., Perales, J.C., Nogueiras, R., Herrero, L., Trifunovic, A., Keller, M.A., Yanes, O., Sales-Pardo, M., Guimerà, R., Blüher, M., Martín-Subero, J.I., Garcia-Roves, P.M.: Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue. Redox Biology. 54, 102353 (2022). https://doi.org/10.1016/j.redox.2022.102353
15. Basso, P.J., Schcolnik-Cabrera, A., Zhu, M., Strachan, E., Clemente-Casares, X., Tsai, S.: Weight Loss-Associated Remodeling of Adipose Tissue Immunometabolism. Obesity Reviews. n/a, e13975. https://doi.org/10.1111/obr.13975
16. Christofides, E.A.: Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes. Clin Diabetes. 37, 234–241 (2019). https://doi.org/10.2337/cd18-0063
17. Hotamisligil, G.S.: Foundations of Immunometabolism and Implications for Metabolic Health and Disease. Immunity. 47, 406–420 (2017). https://doi.org/10.1016/j.immuni.2017.08.009
18. Andreadi, A., Lodeserto, P., Todaro, F., Meloni, M., Romano, M., Minasi, A., Bellia, A., Lauro, D.: Nanomedicine in the Treatment of Diabetes. Int J Mol Sci. 25, 7028 (2024). https://doi.org/10.3390/ijms25137028
19. Desai, N., Chavda, V., Singh, T.R.R., Thorat, N.D., Vora, L.K.: Cancer Nanovaccines: Nanomaterials and Clinical Perspectives. Small. 20, 2401631 (2024). https://doi.org/10.1002/smll.202401631
20. Lu, L., Duong, V.T., Shalash, A.O., Skwarczynski, M., Toth, I.: Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines. Vaccines (Basel). 9, 563 (2021). https://doi.org/10.3390/vaccines9060563
21. Mukerjee, N., Sarkar, S., Uti, D.E., Sharma, P.K.: Advancements in exosome-based cancer diagnosis: from chipsets to nano vaccine. Cancer Biology & Therapy. 26, 2541991 (2025). https://doi.org/10.1080/15384047.2025.2541991
22. Wang, Y., Liu, C., Fang, C., Peng, Q., Qin, W., Yan, X., Zhang, K.: Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy. Nanomicro Lett. 17, 30 (2024). https://doi.org/10.1007/s40820-024-01533-y
23. Yuan, X., Xu, T., Hussain, M., Liu, B., Zhu, J.: Recent advances of nanovaccines on cancer theranostics. Front. Nanotechnol. 7, (2025). https://doi.org/10.3389/fnano.2025.1521131
24. Almohaimeed, H.M., Chowdhury, A., Sarkar, S., Almars, A.I., Tounsi, W.A., Singh, A., Krithiga, T., Ray, S., Uti, D.Ej.: Advances in cancer immunotherapy: The role of super NK and super CAR-T cells. Int Immunopharmacol. 161, 115074 (2025). https://doi.org/10.1016/j.intimp.2025.115074
25. Khanna, D., Welch, B.S., Rehman, A.: Pathophysiology of Obesity. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
26. Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., Cheng, Q.: Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Sig Transduct Target Ther. 10, 93 (2025). https://doi.org/10.1038/s41392-025-02124-y
27. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective

Treatment Against Obesity: A Review of Comparison with Other Actors. Int J Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250

28. Li, M., Yang, Y., Xiong, L., Jiang, P., Wang, J., Li, C.: Metabolism, metabolites, and macrophages in cancer. Journal of Hematology & Oncology. 16, 80 (2023). https://doi.org/10.1186/s13045-023-01478-6
29. Muntjewerff, E.M., Meesters, L.D., van den Bogaart, G.: Antigen Cross-Presentation by Macrophages. Front. Immunol. 11, (2020). https://doi.org/10.3389/fimmu.2020.01276
30. Vesković, M., Šutulović, N., Hrnčić, D., Stanojlović, O., Macut, D., Mladenović, D.: The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach. Curr Issues Mol Biol. 45, 9084–9102 (2023). https://doi.org/10.3390/cimb45110570
31. Thibaut, R., Gage, M.C., Pineda-Torra, I., Chabrier, G., Venteclef, N., Alzaid, F.: Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J. 289, 3024–3057 (2022). https://doi.org/10.1111/febs.15877
32. Bhatti, J.S., Sehrawat, A., Mishra, J., Sidhu, I.S., Navik, U., Khullar, N., Kumar, S., Bhatti, G.K., Reddy, P.H.: Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine. 184, 114–134 (2022). https://doi.org/10.1016/j.freeradbiomed.2022.03.019
33. Zhou, T., Hu, Z., Yang, S., Sun, L., Yu, Z., Wang, G.: Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. J Diabetes Res. 2018, 7457269 (2018). https://doi.org/10.1155/2018/7457269
34. Wusiman, D., Wang, Y., Wang, M., Wang, J., Wu, R., Tuo, Z., Wang, Z., Yu, Q., An, Z., Cho, W.C., Li, D., Wei, W., Feng, D.: Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation. Materials Today Bio. 34, 102116 (2025). https://doi.org/10.1016/j.mtbio.2025.102116
35. He, J., Xiao, W., Hua, D., Liu, M., Guo, H., Xu, L., Xiao, M., Du, Y., Li, J.: Nanovaccines: Innovative Advances from Design Strategies to Clinical Translation. Vaccines. 13, 900 (2025). https://doi.org/10.3390/vaccines13090900
36. Perez-Potti, A., Rodríguez-Pérez, M., Polo, E., Pelaz, B., del Pino, P.: Nanoparticle-based immunotherapeutics: From the properties of nanocores to the differential effects of administration routes. Advanced Drug Delivery Reviews. 197, 114829 (2023). https://doi.org/10.1016/j.addr.2023.114829
37. Azharuddin, M., Zhu, G.H., Sengupta, A., Hinkula, J., Slater, N.K.H., Patra, H.K.: Nano toolbox in immune modulation and nanovaccines. Trends Biotechnol. 40, 1195–1212 (2022). https://doi.org/10.1016/j.tibtech.2022.03.011
38. Adetunji, C.O., Michael, O.S., Rathee, S., Singh, K.R., Ajayi, O.O., Adetunji, J.B., Ojha, A., Singh, J., Singh, R.P.: Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight. Materials Today Advances. 13, 100198 (2022). https://doi.org/10.1016/j.mtadv.2021.100198
39. Loo, C.-Y., Lee, W.-H., Zhou, Q.T.: Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections. Pharm Res. 40, 1015–1036 (2023). https://doi.org/10.1007/s11095-023-03520-1
40. Belančić, A.: Gut microbiome dysbiosis and endotoxemia - Additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes Med. 20, 100302 (2020). https://doi.org/10.1016/j.obmed.2020.100302
41. Mannie, M.D., DeOca, K.B., Bastian, A.G., Moorman, C.D.: Tolerogenic vaccines: targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells. Cell Immunol. 355, 104173 (2020). https://doi.org/10.1016/j.cellimm.2020.104173
42. Kim, C.-G., Lee, J.-C., Ju, D.-B., Kim, S.-K., Yun, C.-H., Cho, C.-S.: Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway. Tissue Eng Regen Med. 20, 355–370 (2023). https://doi.org/10.1007/s13770-023-00527-y
43. Dacoba, T.G., Olivera, A., Torres, D., Crecente-Campo, J., Alonso, M.J.: Modulating the immune system through nanotechnology. Semin Immunol. 34, 78–102 (2017). https://doi.org/10.1016/j.smim.2017.09.007
44. Bhardwaj, P., Bhatia, E., Sharma, S., Ahamad, N., Banerjee, R.: Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater. 108, 1–21 (2020). https://doi.org/10.1016/j.actbio.2020.03.020
45. Kesharwani, P., Kumar, V., Goh, K.W., Gupta, G., Alsayari, A., Wahab, S., Sahebkar, A.: PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy. Mol Cancer. 24, 205 (2025). https://doi.org/10.1186/s12943-025-02410-x
46. Feng, T., Hu, J., Wen, J., Qian, Z., Che, G., Zhou, Q., Zhu, L.: Personalized nanovaccines for treating solid cancer metastases. Journal of Hematology & Oncology. 17, 115 (2024). https://doi.org/10.1186/s13045-024-01628-4
47. Fei, Q., Huang, J., He, Y., Zhang, Y., Zhang, X., Wang, J., Fu, Q.: Immunometabolic Interactions in Obesity: Implications for Therapeutic Strategies. Biomedicines. 13, 1429 (2025). https://doi.org/10.3390/biomedicines13061429

48. Du, Q., Dickinson, A., Nakuleswaran, P., Maghami, S., Alagoda, S., Hook, A.L., Ghaemmaghami, A.M.: Targeting Macrophage Polarization for Reinstating Homeostasis following Tissue Damage. Int J Mol Sci. 25, 7278 (2024). https://doi.org/10.3390/ijms25137278
49. Conte, R., Marturano, V., Peluso, G., Calarco, A., Cerruti, P.: Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds. Int J Mol Sci. 18, 709 (2017). https://doi.org/10.3390/ijms18040709
50. Yu, H.-P., Liu, F.-C., Chung, Y.-K., Alalaiwe, A., Sung, C.T., Fang, J.-Y.: Nucleic acid-based nanotherapeutics for treating sepsis and associated organ injuries. Theranostics. 14, 4411–4437 (2024). https://doi.org/10.7150/thno.98487
51. Khatun, S., Putta, C.L., Hak, A., Rengan, A.K.: Immunomodulatory nanosystems: An emerging strategy to combat viral infections. Biomater Biosyst. 9, 100073 (2023). https://doi.org/10.1016/j.bbiosy.2023.100073
52. Gu, B., Zhao, Q., Ao, Y.: Advances in Immunomodulatory Mesoporous Silica Nanoparticles for Inflammatory and Cancer Therapies. Biomolecules. 14, 1057 (2024). https://doi.org/10.3390/biom14091057

CITE AS: Serunjogi Ruth (2025). Nanovaccines and Immunomodulatory Nanoparticles for Preventing Obesity-Induced Diabetes. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 31-38. https://doi.org/10.59298/IDOSR/JES/112.3138